656 related articles for article (PubMed ID: 19557716)
1. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
[TBL] [Abstract][Full Text] [Related]
2. Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy.
Bazzi C; Rizza V; Casellato D; Stivali G; Rachele G; Napodano P; Olivieri G; Gallieni M; D'Amico G
J Nephrol; 2012; 25(5):810-8. PubMed ID: 22252844
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
4. Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy.
Peters HP; van den Brand JA; Wetzels JF
Neth J Med; 2009 Feb; 67(2):54-61. PubMed ID: 19299847
[TBL] [Abstract][Full Text] [Related]
5. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study.
Manno C; Strippoli GF; D'Altri C; Torres D; Rossini M; Schena FP
Am J Kidney Dis; 2007 Jun; 49(6):763-75. PubMed ID: 17533019
[TBL] [Abstract][Full Text] [Related]
6. Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis.
Woo KT; Lau YK; Zhao Y; Liu FE; Tan HB; Tan EK; Stephanie FC; Chan CM; Wong KS
Cell Mol Immunol; 2007 Jun; 4(3):227-32. PubMed ID: 17601378
[TBL] [Abstract][Full Text] [Related]
7. "Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR.
Komatsu H; Fujimoto S; Sato Y; Hara S; Yamada K; Morita S; Eto T
J Nephrol; 2005; 18(6):690-5. PubMed ID: 16358226
[TBL] [Abstract][Full Text] [Related]
8. In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression.
Bazzi C; Rizza V; Raimondi S; Casellato D; Napodano P; D'Amico G
Clin J Am Soc Nephrol; 2009 May; 4(5):929-35. PubMed ID: 19406958
[TBL] [Abstract][Full Text] [Related]
9. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
[TBL] [Abstract][Full Text] [Related]
10. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
Coppo R; Peruzzi L; Amore A; Piccoli A; Cochat P; Stone R; Kirschstein M; Linné T
J Am Soc Nephrol; 2007 Jun; 18(6):1880-8. PubMed ID: 17513327
[TBL] [Abstract][Full Text] [Related]
11. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy.
Rocchetti MT; Centra M; Papale M; Bortone G; Palermo C; Centonze D; Ranieri E; Di Paolo S; Gesualdo L
Proteomics; 2008 Jan; 8(1):206-16. PubMed ID: 18095357
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
[TBL] [Abstract][Full Text] [Related]
13. Factors predicting progression of IgA nephropathies.
Coppo R; D'Amico G
J Nephrol; 2005; 18(5):503-12. PubMed ID: 16299675
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation.
Kanno Y; Okada H; Yamaji Y; Nakazato Y; Suzuki H
QJM; 2005 Mar; 98(3):199-203. PubMed ID: 15728401
[TBL] [Abstract][Full Text] [Related]
15. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.
Jafar TH; Schmid CH; Stark PC; Toto R; Remuzzi G; Ruggenenti P; Marcantoni C; Becker G; Shahinfar S; De Jong PE; De Zeeuw D; Kamper AL; Strangaard S; Levey AS
Nephrol Dial Transplant; 2003 Oct; 18(10):2047-53. PubMed ID: 13679479
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[TBL] [Abstract][Full Text] [Related]
17. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
Riispere Ž; Kuudeberg A; Seppet E; Sepp K; Ilmoja M; Luman M; Kõlvald K; Auerbach A; Ots-Rosenberg M
BMC Nephrol; 2017 Mar; 18(1):89. PubMed ID: 28292274
[TBL] [Abstract][Full Text] [Related]
18. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.
Kent DM; Jafar TH; Hayward RA; Tighiouart H; Landa M; de Jong P; de Zeeuw D; Remuzzi G; Kamper AL; Levey AS
J Am Soc Nephrol; 2007 Jun; 18(6):1959-65. PubMed ID: 17475813
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.
van der Kleij FG; Schmidt A; Navis GJ; Haas M; Yilmaz N; de Jong PE; Mayer G; de Zeeuw D
Kidney Int Suppl; 1997 Dec; 63():S23-6. PubMed ID: 9407415
[TBL] [Abstract][Full Text] [Related]
20. [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
Shi X; Chen X; Liu S; Zhuang Y; Zhang Y
Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):399-403. PubMed ID: 12137603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
